Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $612K | $589K | $43.5K | $208K | — | — | — | — | — | — |
| Revenue growth | — | -3.6% | -92.6% | 378.3% | — | — | — | — | — | — |
| Operating income | -$5.66M | $10.6M | -$6.54M | $3.51M | -$3.13M | -$4.04M | -$4.43M | -$7.10M | -$14.5M | -$16.1M |
| Operating margin | -924.6% | 1794.2% | -15035.4% | 1685.6% | — | — | — | — | — | — |
| Net income | -$5.41M | $10.3M | -$6.72M | $3.52M | -$2.70M | -$4.07M | -$4.43M | -$7.10M | -$22.6M | -$19.4M |
| Net margin | -884.4% | 1752.2% | -15442.0% | 1690.4% | — | — | — | — | — | — |
| EPS (diluted) | -$1.08 | -$1.87 | -$4.74 | -$0.02 | $0.19 | $0.26 | $0.29 | $34.18 | $4,106.00 | $31.22 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.31M | -$5.90M | -$4.89M | -$3.90M | -$3.50M | -$3.77M | -$3.73M | -$6.56M | -$12.5M | -$15.2M |
| Capital expenditures | $76.5K | $19.5K | $5.37K | $23.0K | $53.0K | $5.00K | $1.00K | — | $104K | $96.0K |
| Free cash flow | -$5.39M | -$5.91M | -$4.90M | -$3.92M | -$3.55M | -$3.77M | -$3.73M | — | -$12.6M | -$15.3M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $149K | $53.8K | $97.1K | $419K | $9.82M | $6.06M | $2.31M | $4.49M | $5.62M | $7.38M |
| Total assets | $2.46M | $1.67M | $688K | $1.10M | $10.6M | $6.26M | $2.44M | $4.91M | $5.93M | $7.84M |
| Total liabilities | $3.37M | $4.82M | $3.56M | $2.51M | $1.62M | $1.11M | $1.21M | $1.71M | $18.9M | $5.01M |
| Shareholders' equity | -$10.9M | -$16.6M | -$2.87M | -$1.41M | $8.98M | $5.16M | $1.23M | $3.20M | -$13.0M | $2.83M |
| Retained earnings | -$35.6M | -$47.4M | -$87.2M | -$90.7M | -$93.4M | -$97.5M | -$102M | -$110M | -$132M | -$152M |
| Shares (wtd avg diluted) | 5.79M | 6.29M | 8.40M | 155M | 196M | 15.5M | 15.5M | 208K | 5.50B | 621K |
Every figure is extracted from Glucotrack, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.